Skye Bioscience (SKYE) Amortizatization of Intangibles (2018 - 2020)
Skye Bioscience (SKYE) posted quarterly Amortizatization of Intangibles of $141409.0 for Q4 2020, down 25.7% year-over-year from $190329.0 in Q1 2020, and up 2.3% quarter-over-quarter from $138233.0 in Q3 2020.
Skye Bioscience (SKYE) Amortizatization of Intangibles (2018 - 2020) Analysis & Trends
Skye Bioscience (SKYE) has reported Amortizatization of Intangibles for 3 consecutive years, with $141409.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Amortizatization of Intangibles fell 25.7% year-over-year to $141409.0; the TTM figure through Dec 2020 stood at $544033.0 (down 13.55% YoY), while the FY2020 annual figure was $544033.0, down 13.55% from the prior year.
- Amortizatization of Intangibles advanced to $141409.0 in Q4 2020 per SKYE's latest filing, from $138233.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $194213.0 in Q3 2019 and bottomed at $23928.0 in Q4 2018.
- Historically, Amortizatization of Intangibles has averaged $123186.2 across 3 years, with a median of $135957.0 in 2020.
- Annual changes were most pronounced in 2019 — Amortizatization of Intangibles soared 695.42% — and 2020, when it dropped 28.82%.
- Skye Bioscience's Amortizatization of Intangibles stood at $23928.0 in 2018, then jumped by 695.42% to $190329.0 in 2019, then decreased by 25.7% to $141409.0 in 2020.
- Business Quant data shows SKYE's Amortizatization of Intangibles at $141409.0 in Q4 2020, $138233.0 in Q3 2020, and $133681.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | 1.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 141,409.00 |
| Dec 31, 2020 | 141,409.00 |
| Sep 30, 2020 | 138,233.00 |
| Sep 30, 2020 | 138,233.00 |
| Jun 30, 2020 | 133,681.00 |
| Jun 30, 2020 | 133,681.00 |
| Mar 31, 2020 | 130,710.00 |
| Mar 31, 2020 | 130,710.00 |
| Dec 31, 2019 | 190,329.00 |
| Dec 31, 2019 | 190,329.00 |
| Sep 30, 2019 | 194,213.00 |
| Sep 30, 2019 | 194,213.00 |
| Jun 30, 2019 | 187,799.00 |
| Jun 30, 2019 | 187,799.00 |
| Mar 31, 2019 | 56,952.00 |
| Mar 31, 2019 | 56,952.00 |
| Dec 31, 2018 | 23,928.00 |
| Dec 31, 2018 | 23,928.00 |
| Mar 31, 2018 | 34,608.00 |
| Mar 31, 2018 | 34,608.00 |